Your browser is no longer supported. Please, upgrade your browser.
EDIT Editas Medicine, Inc. daily Stock Chart
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.76 Insider Own0.10% Shs Outstand55.35M Perf Week18.22%
Market Cap2.26B Forward P/E- EPS next Y-3.27 Insider Trans-5.49% Shs Float53.70M Perf Month0.64%
Income-142.20M PEG- EPS next Q-0.67 Inst Own70.80% Short Float16.51% Perf Quarter40.47%
Sales24.20M P/S93.21 EPS this Y-14.60% Inst Trans4.56% Short Ratio7.81 Perf Half Y31.73%
Book/sh7.71 P/B4.50 EPS next Y-6.50% ROA-26.40% Target Price38.88 Perf Year40.07%
Cash/sh9.21 P/C3.77 EPS next 5Y- ROE-46.60% 52W Range14.01 - 39.96 Perf YTD17.22%
Dividend- P/FCF- EPS past 5Y-46.80% ROI-53.70% 52W High-13.14% Beta2.01
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low147.75% ATR2.15
Employees208 Current Ratio9.00 Sales Q/Q365.20% Oper. Margin- RSI (14)59.79 Volatility7.10% 5.61%
OptionableYes Debt/Eq0.00 EPS Q/Q38.10% Profit Margin- Rel Volume1.87 Prev Close36.84
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout- Avg Volume1.13M Price34.71
Recom2.50 SMA2010.01% SMA5014.12% SMA20030.40% Volume2,126,154 Change-5.78%
Jun-18-20Resumed SunTrust Buy $45
Feb-21-20Initiated Wells Fargo Equal Weight $28
Apr-12-19Initiated Evercore ISI Outperform
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Aug-06-20 04:05PM  
Jul-30-20 12:33PM  
Jul-29-20 08:00AM  
Jul-27-20 04:01PM  
Jul-25-20 11:52AM  
Jul-23-20 04:01PM  
Jul-21-20 07:07AM  
Jul-12-20 08:45AM  
Jul-09-20 07:31AM  
Jul-07-20 09:00AM  
Jul-02-20 11:32AM  
Jun-27-20 10:20PM  
Jun-26-20 04:05PM  
Jun-24-20 05:12AM  
Jun-23-20 09:48PM  
Jun-19-20 08:41AM  
Jun-12-20 06:00AM  
Jun-06-20 11:31AM  
Jun-04-20 08:13AM  
Jun-03-20 07:02AM  
May-29-20 12:00PM  
May-23-20 07:28AM  
May-22-20 07:39AM  
May-18-20 06:21PM  
May-15-20 09:20AM  
May-10-20 09:28AM  
May-08-20 12:38PM  
May-07-20 10:15AM  
May-04-20 08:25AM  
Apr-30-20 08:05AM  
Apr-29-20 09:00AM  
Apr-28-20 12:33PM  
Apr-06-20 08:59AM  
Mar-27-20 11:31AM  
Mar-19-20 10:40AM  
Mar-11-20 09:20PM  
Mar-05-20 08:29AM  
Mar-04-20 05:00AM  
Feb-28-20 09:06AM  
Feb-27-20 02:56PM  
Feb-26-20 05:25PM  
Feb-19-20 04:02PM  
Feb-17-20 07:12AM  
Feb-06-20 12:30PM  
Feb-03-20 11:27AM  
Jan-17-20 02:09PM  
Jan-13-20 09:00AM  
Jan-10-20 04:30PM  
Jan-09-20 09:00AM  
Jan-06-20 11:00PM  
Jan-02-20 09:00AM  
Dec-30-19 04:07PM  
Dec-24-19 12:00PM  
Dec-19-19 09:15AM  
Dec-14-19 08:42PM  
Dec-12-19 11:30AM  
Dec-09-19 06:00PM  
Dec-03-19 01:03AM  
Dec-02-19 11:43AM  
Nov-20-19 09:41AM  
Nov-19-19 10:46AM  
Nov-13-19 10:00AM  
Nov-12-19 08:35AM  
Nov-05-19 08:00AM  
Oct-31-19 04:30AM  
Oct-30-19 11:10AM  
Oct-29-19 04:05PM  
Oct-28-19 06:55PM  
Oct-23-19 10:32AM  
Oct-19-19 10:29AM  
Oct-16-19 12:16PM  
Oct-15-19 06:15PM  
Oct-07-19 07:00AM  
Oct-01-19 08:00AM  
Sep-13-19 10:06AM  
Sep-06-19 03:07PM  
Sep-05-19 09:31AM  
Sep-04-19 12:52PM  
Aug-29-19 08:00AM  
Aug-27-19 09:10AM  
Aug-13-19 08:27PM  
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Albright CharlesEVP/Chief Scientific OfficerJul 15Sale32.223,00096,66028,373Jul 17 05:32 PM
Albright CharlesEVP/Chief Scientific OfficerMay 06Sale25.281513,81731,373May 08 04:17 PM
Albright CharlesChief Scientific OfficerFeb 07Sale26.9562216,76331,524Feb 10 04:34 PM
Albright CharlesChief Scientific OfficerFeb 03Sale26.545,549147,28820,553Feb 04 05:24 PM
Albright CharlesChief Scientific OfficerJan 31Option Exercise0.0017,977026,102Feb 04 05:24 PM
Collins CynthiaCEOAug 19Sale25.835,193134,13511,373Aug 21 04:03 PM